scholarly journals Meta-analysis of effectiveness of traditional Chinese medicine or its combination with Western medicine in the treatment of triple negative breast cancer

2021 ◽  
Vol 18 (3) ◽  
pp. 639-645
Author(s):  
Wang Yukun ◽  
Yao Chang ◽  
He Fan ◽  
Zeng Jiayao
Keyword(s):  
Breast Cancer ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Triple Negative Breast Cancer ◽  
Western Medicine ◽  
Triple Negative ◽  
Controlled Trial ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
Text Data

Purpose: To assess the efficacy and side effects of Traditional Chinese Medicine (TCM) in the management of triple negative breast cancer (TNBC). Methods: Full text data on randomized controlled trial (RCT) of TNBC treated with TCM or its combination with Western Medicine (WM) were retrieved from the Chinese biomedical literature database, Chinese periodicals, Chinese Science-Technology periodicals and VP and PubMed. The qualities of the RCTs were evaluated. Revman 5.3 was used to conduct the meta-analysis. Results: A total of 16 RCTs involving 1186 patients were included. Analysis of these RCTs showed significant differences in total effectiveness between WM and TCM or combination of TCM with WM {(OR = 2.63, 95 % CI = 1.37, 5.03), test of the combined effect (Z = 2.91, p ˂ 0.005)}. Conclusion: The results show that TCM is effective in the treatment TNBC

scholarly journals A meta-analysis of neuroprotective effect for traditional Chinese medicine (TCM) in the treatment of glaucoma

Open Medicine ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Li Chao ◽  
Lu Na ◽  
Li Bin ◽  
Zheng Botao ◽  
Li Shuaijie
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Recovery Rate ◽  
Neuroprotective Effect ◽  
Controlled Trial ◽  
Meta Analysis ◽  
Control Group ◽  
Cochrane Central Register ◽  
Standard Mean Difference

AbstractBackgroundThe aim of this study was to evaluate the neuroprotective effect of surgery combined with traditional Chinese medicine(TCM)in the treatment of glaucoma by meta-analysis based on clinical controlled trial.MethodsAll the prospective randomized controlled trialsof surgery combined with TCM in the treatment of glaucoma were searched in the databases of Medline (1960-2015.1), CENTRAL (the Cochrane central register of controlled trials 1989-2015.1, EMBASE (1980∼2015.1) and CNKI (1979-2015.1). Two reviewers independently assessed the quality of the included studies, extracted the relevant data and performed a cross-check. The pooled relative risk (RR) or standard mean difference (SMD) of surgery combined with TCM versus western medicine or surgery alone were calculated as the effect size by meta-analysis method. All the data was analyzed by stata11.0 software (http://www.stata.com; Stata Corporation, College Station, TX).ResultsFinally, eleven clinical controlledtrails with 843 subjects were included in this meta-analysis. The pooled results indicated that the surgery combined with TCM treatment procedure can significant improve the vision recovery rate compared to control group (RR=1.22, 95% CI:1.06∼1.40, P=0.005); And after treatment, the visual field in combined group was significantly improved compared to control group (SMD=0.26∼95% CI:0.09∼0.43, P=0.003).ConclusionSurgery combined with TCM can improve the vision recovery rate and the visual fieldin the treatment of glaucoma compared to surgery or western medicine alone.

scholarly journals Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Wenjie Zhao ◽  
Jinhua Liu ◽  
Yaqun Li ◽  
Zichao Chen ◽  
Dongmei Qi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
The Body ◽  
Active Ingredients ◽  
Active Components ◽  
Effective Treatment Option ◽  
Risk Of Death

Triple-negative breast cancers are heterogeneous, poorly prognostic, and metastatic malignancies that result in a high risk of death for patients. Targeted therapy for triple-negative breast cancer has been extremely challenging due to the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Clinical treatment regimens for triple-negative breast cancer are often based on paclitaxel and platinum drugs, but drug resistance and side effects from the drugs frequently lead to treatment failure, thus requiring the development of new therapeutic platforms. In recent years, research on traditional Chinese medicine in modulating the immune function of the body has shown that it has the potential to be an effective treatment option against triple-negative breast cancer. Active components of herbal medicines such as alkaloids, flavonoids, polyphenols, saponins, and polysaccharides have been shown to inhibit cancer cell proliferation and metastasis by activating inflammatory immune responses and can modulate tumor-related signaling pathways to further inhibit the invasion of triple-negative breast cancer. This paper reviews the immunomodulatory mechanisms of different herbal active ingredients against triple-negative breast cancer and provides an outlook on the challenges and directions of development for the treatment of triple-negative breast cancer with herbal active ingredients.

scholarly journals Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis

Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 549
Author(s):  
Amal Qattan ◽  
Taher Al-Tweigeri ◽  
Wafa Alkhayal ◽  
Kausar Suleman ◽  
Asma Tulbah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Triple Negative Breast Cancer ◽  
Drug Response ◽  
Triple Negative ◽  
Meta Analysis ◽  
Integrated Analysis ◽  
Circulating Mirnas ◽  
Persistent Problem ◽  
Network Analyses

Resistance to therapy is a persistent problem that leads to mortality in breast cancer, particularly triple-negative breast cancer (TNBC). MiRNAs have become a focus of investigation as tissue-specific regulators of gene networks related to drug resistance. Circulating miRNAs are readily accessible non-invasive potential biomarkers for TNBC diagnosis, prognosis, and drug-response. Our aim was to use systems biology, meta-analysis, and network approaches to delineate the drug resistance pathways and clinical outcomes associated with circulating miRNAs in TNBC patients. MiRNA expression analysis was used to investigate differentially regulated circulating miRNAs in TNBC patients, and integrated pathway regulation, gene ontology, and pharmacogenomic network analyses were used to identify target genes, miRNAs, and drug interaction networks. Herein, we identified significant differentially expressed circulating miRNAs in TNBC patients (miR-19a/b-3p, miR-25-3p, miR-22-3p, miR-210-3p, miR-93-5p, and miR-199a-3p) that regulate several molecular pathways (PAM (PI3K/Akt/mTOR), HIF-1, TNF, FoxO, Wnt, and JAK/STAT, PD-1/PD-L1 pathways and EGFR tyrosine kinase inhibitor resistance (TKIs)) involved in drug resistance. Through meta-analysis, we demonstrated an association of upregulated miR-93, miR-210, miR-19a, and miR-19b with poor overall survival outcomes in TNBC patients. These results identify miRNA-regulated mechanisms of drug resistance and potential targets for combination with chemotherapy to overcome drug resistance in TNBC. We demonstrate that integrated analysis of multi-dimensional data can unravel mechanisms of drug-resistance related to circulating miRNAs, particularly in TNBC. These circulating miRNAs may be useful as markers of drug response and resistance in the guidance of personalized medicine for TNBC.

scholarly journals 54P Overweight and prognosis in triple-negative breast cancer patients: A systematic review and meta-analysis

2021 ◽  
Vol 32 ◽  
pp. S43-S44
Author(s):  
K.S. Harborg ◽  
R. Zachariae ◽  
J. Olsen ◽  
M. Johannsen ◽  
D. Cronin-Fenton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis ◽  
Breast Cancer Patients

Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis

2021 ◽  
Author(s):  
Farah Latif ◽  
Hira Bint Abdul Jabbar ◽  
Hamna Malik ◽  
Humaira Sadaf ◽  
Azza Sarfraz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document